Gambia medical device regulations

Complete version 4 import/export guideline, approved 18 September 2026 and effective 21 September 2026. Expressly replaces version 3 of July 2020. Includes listed products, import and export permits, documentation, manufacturer licensing and GMP evidence, and incorporated application references.

Complete importer-licensing guideline, version 4, approved 18 September 2026 and effective 21 September 2026. Replaces the July 2020 version. Covers responsibilities, new and renewal applications, issuance, refusal, suspension and revocation for importers of medicines and related products.

Complete current MCA listing guideline, approved and effective 19 June 2026. Expressly replaces the earlier guidance to manufacturers, marketing-authorisation holders and importers. Covers listing eligibility, medical devices, application processes, annexes and the reference-country appendix. It cites an amendment Act as 2025, while the earlier guidance and Assembly catalogue refer to 2023; that statutory identity requires separate verification.

Complete MCA emergency-use authorisation guideline, expressly including IVDs. Covers emergency declarations, eligibility, assessment, applicant instructions, conditions and the separate normative/template annex references. The referenced annex originals are maintained as separate corpus expressions.

Complete current-directory guideline on licensing storage facilities for medicines and related products, including application, renewal and inspection requirements. Retains the stated distinction between licensing of government facilities and their inspection obligations.

Complete MCA inspections guideline supplied by the current official directory. Its scope expressly covers medicines and related products and their receipt, storage and distribution systems, inspection categories, premises and inspection preparation. Manufacturing and clinical-trial inspections are separately addressed instruments.

Complete current-directory recall guideline, version 2. Covers notification, initiation, classification, responsibilities, execution and follow-up of recalls for medicines and related products, including manufacturers, importers, distributors and authorisation holders.

Complete MCA safe-disposal guideline from the live authority directory. Applies to regulated medicines and related products and to manufacturers, importers, wholesalers, retailers and health facilities. Its express exclusions for other health-facility wastes, heavy metals and radioactive waste are preserved.

Complete MCA storage and distribution guideline, version 2, supplied by the live authority directory. Covers handling, quality systems, premises, equipment, storage conditions, transport, documentation, returns and related-product responsibilities.

Complete MCA advertising guideline. Expressly applies to related products as defined in the Act and Regulations, including advertising to the public and professionals, sales representatives and sponsored promotional meetings. Original annex and application references are retained.

Complete one-page adverse-event and serious-adverse-event line-listing form, version 1 dated 24 January 2025. The twelve-column clinical-trial table includes its printed example row, blank cells and investigational medicinal product references; it is also referenced by the trial progress report. Example dates and outcomes are not legal deadlines or general device vigilance rules. Later revisions and current applicability remain unverified.

Complete one-page investigator declaration, version 2 dated 24 January 2025. It includes investigator role choices and declarations about trial duties, conflicts of interest and previous GCP or ethical closures. The source identifies the form as MCA-F-501/11 in the header and MCA-T-501/11 in the footer; this discrepancy is retained without choosing or inventing a corrected official code. Later revisions and current applicability remain unverified.

Complete two-page serious adverse event report form, version 2 dated 24 January 2025, retained as part of the common clinical-trial reporting family. It records participant and event information, causality, report type and investigator signature. Its explicit investigational medicinal product, dose and concomitant-medication headings remain unchanged and are not recast as universal medical-device vigilance requirements. Later revisions and current applicability remain unverified.

Complete one-page sponsor indemnification template for sites and investigators, version 2 dated 24 January 2025, retained as necessary common clinical-trial context. The document expressly labels its text as suggested wording and guidance rather than an exclusive approach. Its compound and indemnity wording is preserved without turning the template into a universal device approval requirement. Later revisions and current applicability remain unverified.

Complete two-page clinical trial amendment form, version 3 dated 24 January 2025. It identifies the protocol and trial, related document revisions and a five-column table for current text, proposed changes, summaries and justifications. Its amendment process concerns clinical trials, including the common medical-device trial context, and is not a general device marketing modification route. Later revisions and current applicability remain unverified.

Complete eight-page clinical trial application, version 2 dated 24 January 2025. It expressly includes medical devices among investigational products and records trial identity, sponsors, investigators, sites, product details and applicant declarations. Conditional medicinal-product fields and phase terminology are preserved as printed; they are not imposed on every medical-device or diagnostic study. Later revisions and current applicability remain unverified.

Complete two-page end-of-clinical-trial notification, version 1 dated 24 February 2025. It distinguishes the end in The Gambia, the global end and early termination, and requests two submissions if national and global end dates differ. Its reference to applicable clinical summary-report deadlines supplies no numerical general device-market deadline. The second-page Clinical Trial Progress Report header is preserved as printed. Later revisions and current applicability remain unverified.

Complete one-page clinical trial import application, version 2 dated 24 January 2025. The form offers medicine and related-product choices and collects trial identifiers, product role, batch and expiry, quantity, blinding, storage and port of entry. It belongs to the common clinical-trial process and does not establish a general device market-import procedure, fee or processing deadline. Later revisions and current applicability remain unverified.

Complete four-page clinical trial progress report, version 2 dated 24 February 2025. It records study and site progress, participants, adverse events, trial changes, amendments and protocol or GCP deviations. It states that added trial sites should be submitted as an amendment and contains a conditional ethics-opinion review note; neither is a general device marketing variation rule or market-processing deadline. Both printed SECTION G headings are retained. Later revisions and current applicability remain unverified.

Complete four-page clinical trial or study summary report, version 2 dated 24 January 2025. It covers design, participants, investigational products, accountability, end points, adverse events, modifications and overall results. The printed Stusy spelling and medicinal-product references are preserved. It does not set a national device marketing approval deadline or a general product-variation requirement. Later revisions and current applicability remain unverified.

MCA clinical-trial guideline version 4, dated 24 February 2025. Its investigational-product definition expressly includes medical devices and diagnostics. Covers common trial authorisation, ethics and consent, amendments, trial-related import/export, safety reporting, notifications and record retention, with three flow charts and three appendices. Medicine-phase, IMP and drug-safety branches retain their original product-specific qualifications and are not general device obligations. The cover lists version 4 Effective Date as 21 February, approval as 24 February and coming into effect as 26 February 2025; no effective date is inferred. Present validity and incorporated dependencies remain unverified.

Official Excel medical-device listing form, version 4, dated 19 June 2026 in the current MCA form catalogue. The original workbook is archived unchanged. The reading view transcribes each populated source row with cell coordinates, including applicant status, product identification, intended use, pack size, manufacturer, reference-country approval and declarations; all worksheets and cell notes/validations are considered.

Complete official Annex 1 to the MCA EUA guideline, specifying electronic submission organisation and format. Retained as a separate original alongside the parent guideline, which includes IVDs.

Complete official two-page pre-submission meeting application attached to MCA-GL-120, which includes in-vitro diagnostics. Preserves applicant, proposed dossier, meeting objectives, attendees and scheduling fields.

Complete official Annex 3 specifying information for an EUA submission, including available approvals, manufacturing, safety, effectiveness and emergency-use information. The parent guideline's product scope includes IVDs; annex content is retained as supplied without extending medicine-specific statements to devices.